Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 980

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase

Craft, Noah, Shostak, Yuriy, Carey, Michael, Sawyers, Charles L.·1999·Nature Medicine
DOI 10.1038/6495
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/6495

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 43

  1. Talpin, M.E. et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N. Engl. J. Med. 332, 1393 –1398 (1995). · DOI · Paper page
  2. Gaddipati, J.P. et al. Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res. 54, 2861–2864 (1994).
  3. Veldscholte, J. et al. The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J. Steroid Biochem. Mol. Biol. 41, 665–669 (1992). · DOI · Paper page
  4. Ignar-Trowbridge, D.M. et al. Coupling of dual signaling pathways: epidermal growth factor action involves the estrogen receptor. Proc. Natl. Acad. Sci. USA 89, 4658–4662 ( 1992). · DOI · Paper page
  5. Power, R.F., Mani, S.K., Codina, J., Conneely, O.M. & O'Malley, B.W. Dopaminergic and ligand-independent activation of steroid hormone receptors. Science 254, 1636–1639 (1991). · DOI · Paper page
  6. Aronica, S.M. & Katzenellenbogen, B.S. Stimulation of estrogen receptor-mediated transcription and alteration in the phosphorylation state of the rat uterine estrogen receptor by estrogen, cyclic adenosine monophosphate, and insulin-like growth factor-I. Mol. Endocrinol. 7, 743–752 (1993).
  7. Denner, L.A., Weigel, N.L., Maxwell, B.L., Schrader, W.T., & O'Malley, B.W. Regulation of progesterone receptor-mediated transcription by phosphorylation. Science 250, 1740–1743 (1990). · DOI · Paper page
  8. Culig, Z. et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epiderman growth factor. Cancer Res. 54, 5474– 5478 (1994).
  9. Slamon, D.J. et al. Studies of the Her-2/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707– 712 (1989). · DOI · Paper page
  10. Adnane, J. et al. Proto-oncogene amplification and human breast tumor phenotype. Oncogene 4, 1389–1395 (1989).
  11. Zeillinger, R. et al. HER-2 amplification, steroid receptors and epidermal growth factor receptor in primary breast cancer. Oncogene 4, 109–114 (1989).
  12. Borg, A. et al. ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett. 81, 137–144 (1994). · DOI · Paper page
  13. Leitzel, K. et al. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J. Clin. Oncol. 13, 1129–1135 (1995). · doi:10.1200/jco.1995.13.5.1129
  14. Pietras, R.J. et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10, 2435–2446 ( 1995).
  15. Ware, J.L., Maygarden, S.J., Koontz, W.W. Jr. & Strom, S.C. Immunohistochemical detection of c-erbB-2 protein in human benign and neoplastic prostate. Hum. Pathol. 22, 254–258 (1991). · doi:10.1016/0046-8177(91)90159-m
  16. Robinson, D., He, F., Preglow, T. & Kung, H.J. A tyrosine kinase profile of prostate carcinoma. Proc. Natl. Acad. Sci. USA 93, 5958–5962 (1996). · DOI · Paper page
  17. Lyne, J.C. et al. Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biological effects on prostate cancer cells in vitro. Cancer J. Sci. Am. 3, 21–30 (1997).
  18. Mellon, K. et al. p53, c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostate. J. Urol. 147, 496–499 (1992). · DOI
  19. Kuhn, E.J., Kurnot, R.A., Sesterhenn, I.A., Chang, E.H. & Moul, J.W. Expression of the c-erb-B-2 (HER-2/neu) oncoprotein in human prostatic carcinoma. J. Urol. 150, 1427–1433 (1993). · DOI · Paper page
  20. Sadasivan, R. et al. Overexpression of HER-2/Neu may be an indicator of poor prognosis in prostate cancer. J. Urol. 150, 126– 131 (1993). · DOI
  21. Ross, J.S. et al. Prognostic significance of HER-2/neu gene amplification status by fluorescence in situ hybridization of prostate carcinoma. Cancer 79, 2162–2170 ( 1997). · doi:10.1002/(sici)1097-0142(19970601)79:11<2162::aid-cncr14>3.0.co;2-u
  22. Arai, Y., Tatsuhiro, T. & Yoshida, O. c-erbB-2 oncoprotein: a potential biomarker of advanced prostate cancer. Prostate 30, 195– 201 (1997). · doi:10.1002/(sici)1097-0045(19970215)30:3<195::aid-pros8>3.0.co;2-l
  23. Klein, K.A. et al. Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nature Med. 3, 402–408 (1997). · DOI · Paper page
  24. Romijn, J.C., Verkoelen, C.F. & Schroeder, F.H. Application of the MTT assay to human prostate cancer cell lines in vitro: establishment of test conditions and assessment of hormone-stimulated growth and drug-induced cytostatic and cytotoxic effects. Prostate 12, 99–110 (1988). · doi:10.1002/pros.2990120112
  25. Nagabhushan, M. et al. CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. Cancer Res. 56, 3042–3046 (1996).
  26. Kyprianou, N., English, HF. & Isaacs, JT. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res. 50, 3748–3753 (1990).
  27. Wolf, D.A., Schulz, P. & Fittler, F. Transcriptional regulation of prostate kallikrein-like genes by androgen. Mol. Endocrinol. 6, 753 –762 (1992).
  28. Cleutjens, K.B.J.M. et al. An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen promoter. Mol. Endocrinol. 11, 148 –161 (1997). · DOI · Paper page
  29. Schurr, E.R. et al. Prostate-specific antigen expression is regulated by an upstream enhancer. J. Biol. Chem. 271, 7043– 7051 (1996). · DOI · Paper page
  30. Pang, S. et al. Identification of a positive regulatory element responsible for tissue-specific expression of prostate-specific antigen. Cancer Res. 57, 495–499 ( 1997).
  31. Wang, E.H., Zou, S. & Tjian, R. TAFII250-dependent transcription of cyclin A is directed by ATF activator proteins. Genes Dev. 11, 2658– 2669 (1997). · DOI
  32. Riegman, P.H.J., Vlietstra, R.J., van der Korput, J.A.G.M., Brinkmann, A.O. & Trapman, J. The promoter of the prostate-specific antigen gene contains a functional androgen responsive element. Mol. Endocrinol. 5, 1921– 1930 (1991). · DOI · Paper page
  33. Chan, J.M. et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279, 563– 566 (1998). · DOI · Paper page
  34. Burfeind, P., Chernicky, C.L., Rininsland, F. & Ilan, J. Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cell in vivo . Proc. Natl. Acad. Sci. USA 93, 7263 –7268 (1996). · DOI · Paper page
  35. Ben-Levy, R., Paterson, H.F., Marshall, C.J. & Yarden, Y. A single autophosphorylation site confers oncogenicity to the Neu/ErbB-2 receptor and enables coupling to the MAP kinase pathway. EMBO J. 13, 3302–3311 (1994). · DOI · Paper page
  36. Bunone, G., Briand, P.-A., Miksicek, R.J. & Picard, D. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J. 15, 2174–2183 (1996). · DOI · Paper page
  37. Janknecht, R. & Hunter, T. A growing coactivator network. Nature 383, 22–23 ( 1996). · DOI · Paper page
  38. Glass, C.K., Rose, D.W. & Rosenfeld, M.G. Nuclear receptor coactivators. Curr. Opin. Cell. Biol. 9, 222–232 ( 1997). · DOI · Paper page
  39. Cobleigh, M.A. et al. Efficacy and safety of HerceptinTM (humanized anti-HER2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer. Progr/Proc. Am. Soc. Clin. Oncol. 17, 97a (1998).
  40. Slamon, D. et al. Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anticancer activity: a randomized, multinational controlled phase III trial. Progr/Proc. Am. Soc. Clin. Oncol. 17, 98a (1998).
  41. Chazin, V.R., Kaleko, M., Miller, A.D. & Slamon, D.J. Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor. Oncogene 7, 1859– 1866 (1992).
  42. Emami, K.H. & Carey, M. A synergistic increase in potency of a multimerized VP16 transcriptional activation domain. EMBO J. 11, 5005–5012 ( 1992). · DOI
  43. Raitano, A.B., Halpern, J.R., Hambuch, T.M. & Sawyers, C.L. The Bcr-Abl leukemia oncogene activates Jun Kinase and requires Jun for transformation. Proc. Natl. Acad. Sci. USA 92, 11746– 50 (1995). · DOI · Paper page

Cited by

See all 980

Metadata

Authors
Craft, N., Shostak, Y., Carey, M., & Sawyers, C. L.
Venue
Nature Medicine
Publisher
Springer Science and Business Media LLC
Published
1999-03
Volume
5
Issue
3
Pages
280-285
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
DOI
10.1038/6495
OpenAlex
W1580523172
Cited by
980
References
2
FWCI
56.06
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. https://app.cochat.ai/papers/10.1038/6495
The paper
Craft, N., Shostak, Y., Carey, M., & Sawyers, C. L. (1999). A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nature Medicine. https://doi.org/10.1038/6495

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.